Longevity & Aging · Metabolic & Cardiometabolic
testosterone and TRT does-not-straightforwardly-cause prostate cancer per the saturation model
In plain terms: Does taking testosterone give you prostate cancer?
The old "testosterone feeds prostate cancer" fear is not supported by modern data — androgen receptors saturate at low T, and TRT has not been shown to raise prostate-cancer risk in reassuring but non-randomized evidence.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (10)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ory 2016 · J Urol | observational | supports | moderate | Independent cohort: TRT in men with treated/untreated prostate cancer did not produce the expected cancer progression, consistent with saturation model. |
| Androgen Society 2024 · Mayo Clin Proc | observational | supports | moderate | Position paper notes TRAVERSE found no excess prostate-cancer events with TRT vs placebo, supporting non-causation at the population level. |
| Kaplan 2016 · Eur Urol | observational | supports | moderate | Reviews the paradigm shift showing no consistent increase in prostate cancer development or progression with testosterone therapy in men with cancer history. |
| Klotz 2015 · Nat Rev Urol | observational | contradicts | moderate | Argues the saturation model oversimplifies AR biology and that existing data cannot exclude testosterone-driven prostate cancer stimulation or excess risk. |
| Muller 2012 · Eur Urol | observational | supports | high | In the REDUCE placebo arm, serum testosterone and DHT showed no association with prostate cancer risk, supporting a saturation effect at low androgen levels. |
| Garcia-Becerra CA et al. 2026 · Int J Impot Res | meta-analysis | supports | high | Meta 41 RCTs: no increased prostate-cancer events with testosterone therapy (OR 0.88) - consistent with the saturation model. |
| Bhasin 2024 · J Clin Endocrinol Metab | RCT | supports | high | Synthesis of large RCTs (esp. TRAVERSE) shows testosterone therapy did not increase high-grade or any prostate cancer versus placebo in screened hypogonadal men. |
| Alexandre Alves 2026 · Cureus | observational | supports | moderate | Systematic review finds TRT does not increase biochemical recurrence, progression, or mortality in low/intermediate-risk prostate cancer, consistent with the saturation model. |
| Davidson 2016 · Urol Clin North Am | observational | supports | moderate | Reviews the saturation model: androgen stimulation of prostate maxes out near about 250 ng/dL; TRT in men with prostate-cancer history has been reassuring — but explicitly notes NO prospective controlled trials exist. |
| Santucci 2025 · BJU Int | observational | mixed | moderate | 2025 systematic review of TRT in localized prostate cancer: observational data broadly reassuring on oncologic safety, but evidence quality is low and no RCTs — cannot exclude harm. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.